According to new research, administering a three-pronged combination immunotherapy regimen to patients with operable pancreatic cancers is safe, increases the number of cancer-killing immune system T cells in the tumors, and appears effective when administered two weeks prior to cancer removal surgery. This regimen includes the immune checkpoint therapy nivolumab and urelemb, an anti-CD137 agonist antibody treatment.
Pancreatic cancer vaccine plus immunotherapy and antibody spark immune system response in pancreatic cancers
